Trophos Explained

Trophos
Founded:	Marseille, France
Fate:	Acquired by Hoffmann-La Roche
Type:	Privately held company

Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.

Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622),^{[1] [2]} a mitochondrial targeted compound developed to treat neurodegenerative diseases.^{[3] [4]}

In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for upfront and up to in milestone performance payments.^{[5] [6]} The deal was completed shortly afterwards.

Further reading

• 10.1016/j.bcp.2010.04.018. 20417191. Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells. Biochemical Pharmacology. 80. 6. 884–894. 2010. Rovini. Amandine. Carré. Manon. Bordet. Thierry. Pruss. Rebecca M.. Braguer. Diane.
• 10.1016/j.pain.2009.09.006. 19833436. 2787910. Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain. 147. 1–3. 202–9. 2009. Xiao. Wen Hua. Zheng. Felix Y.. Bennett. Gary J.. Bordet. Thierry. Pruss. Rebecca M..
• 10.1124/jpet.108.139410 . 18492948 . Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy . Journal of Pharmacology and Experimental Therapeutics . 326 . 2 . 623–632 . 2008 . Bordet . T. . Buisson . B. . Michaud . M. . Abitbol . J.-L. . Marchand . F. . Grist . J. . Andriambeloson . E. . Malcangio . M. . Pruss . R. M. . 33726393 .

Notes and References

1. 10.1124/jpet.107.123000. 17496168. Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis. Journal of Pharmacology and Experimental Therapeutics. 322. 2. 709–720. 2007. Bordet. T.. Buisson. B.. Michaud. M.. Drouot. C.. Galea. P.. Delaage. P.. Akentieva. N. P.. Evers. A. S.. Covey. D. F.. Ostuni. M. A.. Lacapere. J.-J.. Massaad. C.. Schumacher. M.. Steidl. E.-M.. Maux. D.. Delaage. M.. Henderson. C. E.. Pruss. R. M.. 17271734 .
2. Web site: olesoxime. UKMi New Drugs Online Database. 2 January 2016.
3. Web site: Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy. 5 February 2010 . ClinicalTrials.gov . 3 October 2010.
4. Web site: Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS). May 2010 . ClinicalTrials.gov . 3 October 2010.
5. News: Roche buys France's Trophos to expand in neuromuscular disease. Franklin. Joshua. 16 January 2015. 30 December 2015. Reuters.
6. News: Roche to Buy Trophos for Up-to-$543M. Staff. 15 February 2015. Genetic Engineering & Biotechnology News. paper. 6. 35. 4.